Form 4/A for BLFS BIOLIFE SOLUTIONS INC
Accepted 2023-05-16 00:00:00 ET · period of report 2023-03-31 · accession 0001437749-23-014864 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2023-05-16 | 2023-03-31 | BLFS | Mathew Aby J. | EVP, CSO | M - OptEx | — | +4,891 | 275.3K | +2% | — |
| DA | 2023-05-16 | 2023-04-06 | BLFS | Mathew Aby J. | EVP, CSO | S - Sale+OE | $20.03 | -2,093 | 273.2K | -0.8% | -$41.9K |
| DA | 2023-05-16 | 2023-03-31 | BLFS | Mathew Aby J. | EVP, CSO | M - OptEx | $0.00 | -4,891 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-31 | M | A | 4,891 | — | 275,336 | D | — | — | (F1) The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |
| 2 | Common | Common Stock | 2023-04-06 | S | D | 2,093 | $20.03 | 273,243 | D | — | — | (F3) This reflects the total amount beneficially owned by the reporting person as of April 10, 2023. Subsequent Form 4's filed by the reporting person after April 10, 2023 do not currently reflect the vesting of the 4,891 shares. |
| 3 | Derivative | Restricted Stock Award | 2023-03-31 | M | D | 4,891 | $0.00 | 0 | D | $0.00 · — to — | 4,891 Common Stock | (F1) The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 100% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2021 through December 31, 2022 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date). |